Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A PHASE 1B, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY AND PRELIMINARY EFFICACY OF CEMSIDOMIDE IN COMBINATION WITH ELRANATAMAB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA SUBJECTS

Next Previous
Trial Profile

A PHASE 1B, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY AND PRELIMINARY EFFICACY OF CEMSIDOMIDE IN COMBINATION WITH ELRANATAMAB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA SUBJECTS

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Mar 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cemsidomide (Primary) ; Dexamethasone (Primary) ; Elranatamab (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Sponsors C4 Therapeutics

Most Recent Events

  • 23 Feb 2026 According to C4 Therapeutics media release, further analysis of the completed Phase 1 trial of cemsidomide in combination with dexamethasone is expected in mid-2026.
  • 23 Feb 2026 According to C4 Therapeutics media release, Phase 1b trial of cemsidomide in combination with elranatamab is on track to initiate in Q2 2026.
  • 29 Jan 2026 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top